Table 3 Adverse events, according to the treatment
|  | S-1 (n = 61) | Platinum-based doublets (n = 105)a |  | ||||||
|---|---|---|---|---|---|---|---|---|---|
Events | Total, n | Grade I/II, n | Grade III/IV, n | Grade III/IV, (%) | Total, n | Grade I/II, n | Grade III/IV, n | Grade III/IV, (%) | pb |
Any events | 90 | 82 | 8 | – | 249 | 204 | 45 | – | – |
Thrombocytopenia | 7 | 6 | 1 | 1.6 | 41 | 25 | 16 | 15.2 | 3.2e-4* |
Anemia | 22 | 19 | 3 | 4.9 | 58 | 49 | 9 | 8.6 | 0.026* |
Neutropenia | 3 | 2 | 1 | 1.6 | 22 | 17 | 5 | 4.8 | 0.010* |
Renal insufficiency | 5 | 5 | 0 | 0 | 19 | 15 | 4 | 3.8 | 0.129 |
Hepatitis | 13 | 11 | 2 | 3.3 | 15 | 13 | 2 | 1.9 | 0.342 |
Anorexia | 22 | 22 | 0 | 0 | 37 | 33 | 4 | 3.8 | 0.952 |
Diarrhea | 9 | 9 | 0 | 0 | 10 | 9 | 1 | 1.0 | 0.443 |
Vomiting | 6 | 6 | 0 | 0 | 31 | 30 | 1 | 1.0 | 3.5e-3* |
Mucositis | 1 | 1 | 0 | 0 | 5 | 4 | 1 | 1.0 | 0.416 |
PPE | 0 | 0 | 0 | 0 | 9 | 8 | 1 | 1.0 | – |
Skin eruptions | 2 | 1 | 1 | 1.6 | 2 | 1 | 1 | 1.0 | 0.625 |